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Abstract In August 2006, the Australian government
approved subsidized trastuzumab therapy for human epi-
dermal growth factor receptor 2 (HER2)-positive early
breast cancer, and it was mandated that HER2 testing
should be performed using in situ hybridization (ISH)
rather than immunohistochemistry (IHC). Here we review
results of the first regulated, nationwide program to provide
HER2 ISH testing for all newly diagnosed breast cancer
patients, with a particular emphasis on cases where IHC
and ISH results were discordant. Data from all laboratories
participating in the program were collated. Cases with an
equivocal ISH test result [by chromogenic ISH (CISH) or
silver ISH (SISH)] were tested centrally by fluorescence
ISH. Most laboratories also performed HER2 IHC, and 200
cases with discordant IHC and ISH results were selected
for further analysis in a central laboratory. A total of 26
laboratories were involved and 53,402 tests were reported.
Over a 4-year period the HER2 positivity rate decreased for
primary cancers from 23.8 to 14.6 %, but remainedDeclaration The authors declare that the experiments described
comply with the current laws of Australia.
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relatively constant for samples from metastases. Average
ISH reporting times were \5 days for all yearly reporting
periods. Test-repeat rates decreased for CISH (8.9–3.6 %)
and SISH (13.7–8.4 %). Only 12 of 196 cases remained
discordant after retesting in a central laboratory. These
findings demonstrate the successful implementation of a
regulated, national program that continues to collect data
on HER2 status. The results also highlight the differences
in IHC interpretation between local laboratories and a
central, more experienced, laboratory. This model could be
used to establish future biomarker-testing programs in
other countries.




ASCO American Society of Clinical Oncology
CAP College of American Pathologists
CEP17 Chromosome enumeration probe 17
Chr Chromosome
CISH Chromogenic in situ hybridization
EBC Early breast cancer
FISH or (f) Fluorescence in situ hybridization
HER2 Human epidermal growth factor receptor 2
IHC Immunohistochemistry
ISH In situ hybridization
MBC Metastatic breast cancer
SISH or (s) Silver in situ hybridization
Introduction
The human epidermal growth factor receptor 2 (HER2)
gene is amplified in *15–20 % of breast cancers and has
been linked with poor prognosis [1–6], making it an
attractive molecular target for breast cancer therapy.
Trastuzumab (Herceptin; F. Hoffmann-La Roche Ltd,
Basel, Switzerland) is an anti-HER2 monoclonal antibody
with proven survival benefits in the treatment of women
with HER2-positive metastatic breast cancer (MBC) [7–11]
and early breast cancer (EBC) [12–15]. Evaluation of the
HER2 status of all breast cancers at diagnosis is recom-
mended to predict the potential benefit from trastuzumab
treatment [16, 17].
HER2 testing is performed by either immunohisto-
chemistry (IHC) or in situ hybridization (ISH). IHC uses
anti-HER2 antibodies to detect HER2 protein expression
levels, and is assessed semiquantitatively by the proportion
and intensity of staining. ISH uses DNA probes to deter-
mine HER2 gene copy number. To ensure accurate HER2
testing, as well as consistent and appropriate patient
selection for trastuzumab therapy, the American Society of
Clinical Oncology (ASCO) and the College of American
Pathologists (CAP) convened an expert panel to compile
and publish HER2 testing recommendations that included
an algorithm to define positive, negative, and equivocal
HER2 results according to both HER2 protein expression
and gene amplification [18]. According to the ASCO/CAP
guidelines, a HER2-positive result by IHC is uniform,
intense staining of[30 % of invasive tumor cells (3?) and
a positive result by ISH is [6 HER2 gene copies per
nucleus or a HER2 gene:chromosome enumeration probe
17 (CEP17) signal ratio of [2.2 [18].
A minority of the ASCO/CAP panel expressed the view
that IHC is not a sufficiently accurate assay to determine
HER2 status [18], and two large trials have shown dis-
cordance between local and central HER2 testing by IHC
[19] or by both IHC and fluorescence ISH (FISH) [20].
Analysis of concordance between a local and a high-vol-
ume central laboratory in a phase IV trial [21] also showed
poor concordance of IHC results, and concluded that HER2
testing is most accurate when performed at a high-volume
central laboratory.
In Australia, *14,000 new breast cancer cases are
diagnosed annually [22]. Patients with HER2-positive
MBC, determined by either IHC or ISH, are eligible for
trastuzumab therapy as part of the Herceptin program
administered by Medicare Australia. Patients with HER2-
positive EBC are also eligible for trastuzumab therapy
under the Australian government-funded Pharmaceutical
Benefits Scheme. The Pharmaceutical Benefits Advisory
Committee specified that HER2 positivity should be dem-
onstrated by ISH in these patients. This requirement led to
the development of the Australian In Situ Hybridization
Program, a nationwide program utilizing ISH as the HER2
testing platform. The program was launched as a multi-
center, coordinated project, with the primary objective
being to provide accurate tumor ISH testing for all patients
diagnosed with EBC. Accurate testing is critical in guiding
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the provision of trastuzumab therapy to those who are
likely to derive the most benefit from the treatment.
Here, we include details of the HER2 positivity rates
recorded across Australia from October 2006 to September
2010 for patients with EBC or MBC, along with other test-
related data; including result turnaround times and repeat
testing rates. Most laboratories continue to use IHC in
parallel with ISH and we also document the results of a
reevaluation of 200 samples that had shown discordance




The Australian In Situ Hybridization Program is a nation-
wide, multicenter, coordinated project sponsored by Roche
Products Pty Limited (Dee Why, Australia) and overseen
by the Australian HER2 Testing Advisory Board. Details
of establishing of this program, including identification,
training, certification, and accreditation of all laboratories,
as well as the implementation of standardized reporting
protocols, have been described previously [22].
Sample selection
The majority of samples for HER2 ISH testing were from
excised tumors from women aged C18 years with EBC or
MBC. Approximately 10 % of samples were core biopsies
and \1 % were from fine needle aspiration cell block
material, or from male breast cancer patients.
HER2 testing
All local laboratories were responsible for the provision of
an accurate and timely HER2 testing service to support
clinical decision-making in their area. Figure 1 shows the
ISH assay algorithm used to determine HER2 positivity. A
validated single-probe ISH test was used for all samples,
with a CEP17 probe used for equivocal cases, defined as
4–6 HER2 signals per nucleus. Cases that remained
equivocal following dual-probe testing (defined as a
HER2:CEP17 ratio of 1.8–2.2) or which were non-diag-
nostic due to a weak signal, were sent to a central reference
laboratory for FISH testing using the PathVysion kit
(Vysis/Abbott, Illinois, USA). IHC was used in conjunction
with ISH as a quality control, both to assess tumor heter-
ogeneity and to assist in the overall assessment of difficult-
to-assess cases. In the initial phase of the program, IHC
was used by some laboratories lacking the facility to per-
form ISH, to triage cases to be sent for ISH testing at one of
the program laboratories. This practice gradually dimin-
ished over time, such that the vast majority of invasive
cancer cases were submitted for ISH testing regardless of
whether IHC had been performed, or of the IHC result.
All laboratories initially used a chromogenic ISH kit
(CISH; SPoT-Light CISH, Invitrogen, California, USA).
Approximately 1 year after the launch of the program,
silver ISH (SISH; Inform
TM
, Ventana Medical Systems,
Inc., Arizona, USA) was also included as an alternative
ISH testing assay, with a third option (DuoCISH
TM
, Dako,
Glostrup, Denmark) included 6 months later. All kits were
used in accordance with the ISH assay algorithm (Fig. 1)
and, from March 2008, the scoring of all HER2 tests
adhered to the 2007 ASCO/CAP recommendations [18].
Data collection
All HER2 test results, reporting times, test-repeat rates, and
the proportion of tests performed on core biopsies were
recorded. Means of each parameter were calculated for
each laboratory and state during the measurement periods
of October–September for 2006–2007, 2007–2008,
2008–2009, and 2009–2010. Mean HER2 positivity rates
were also calculated for each laboratory and state for the
four 12-month time periods.
Comparison of IHC and ISH results
Two hundred invasive carcinomas were selected from
patients, in which IHC had been performed at a local
laboratory and the paraffin blocks or unstained sections had
been forwarded to a central reference laboratory for ISH
testing. All selected cases had shown discordance between
local IHC and central ISH results. The cases included were
Single probe
CEP17 probe
4-6 copies = 
equivocal
<4 copies = 
negative
>6 copies = 
positive
Ratio 1.8-2.2 = 
equivocal
Ratio <1.8 = 
negative




Fig. 1 In situ hybridization assay algorithm for determining human
epidermal growth factor receptor 2 status and eligibility for
trastuzumab therapy in Australia. CEP17 chromosome enumeration
probe 17, FISH fluorescence in situ hybridization
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either IHC 0/IHC 1? that showed HER2 gene amplifica-
tion (false-negative, n = 31) or IHC 3? that showed no
HER2 gene amplification (false-positive, n = 169). The
central laboratory performed IHC on archived, unstained
sections from all the cases using the 4B5 antibody (Ven-
tana Medical Systems, Inc.) on the Ventana BenchMark
Immunostainer (Ventana Medical Systems, Inc.). The
stained slides were then assessed by a pathologist blinded
to both the original IHC result, and to the HER2 gene
amplification status. In cases of uncertainty a second
pathologist independently assessed the slide and, if nec-
essary, the case was viewed by both pathologists together
and a consensus score reached.
Results
HER2 positivity rates
By September 2010, the Australian In Situ Hybridization
Program had been running for 4 years and had performed
53,402 ISH tests. Overall, 26 laboratories were approved
for ISH testing. In the final reporting period, eight labo-
ratories used CISH and 18 used SISH assays.
The total number of ISH tests conducted between
October 2006 and September 2010, as well as the HER2
positivity rates for samples from EBC and MBC, are shown
in Tables 1 and 2. Between October 2006 and September
2010, the overall HER2 ISH positivity rate was 16.9 % for
EBC and 22.5 % for MBC. The HER2 positivity rate for
EBC decreased each year from 23.8 % in the first
12-month period to 14.6 % in the final 12 months, whereas
the MBC HER2 positivity rate varied from 22.6 % in the
first 12-month period to 25.1, 21.3, and 21.6 % in the
second, third, and fourth 12-month periods, respectively.
The majority of tumor specimens used for HER2 testing
were obtained from excised tumors. The proportion of core
biopsy samples tested remained consistently low and rarely
exceeded 10 %. Testing of core biopsies was actively
discouraged unless the HER2 status was required for a
clinical decision regarding neoadjuvant therapy.
Reporting time data were provided by 17 of 18 labora-
tories in the first 12 months, 20 of 22 laboratories in the
second 12 months, and all 26 laboratories in the final two
12-month periods. The average ISH reporting time from
the date of the request for a HER2 test remained relatively
unchanged between the reporting periods (4.9, 4.7, 4.6, and
4.5 days, respectively). For individual laboratories, average
reporting times ranged from 1.3 to 12.9 days in the first
12 months, from 1.6 to 10.5 days in the second 12 months,
from 1.0 to 10.2 days in the third 12 months, and from 1.3
to 10.9 days in the final 12 months. Average reporting
times were longer than 7 days for 2 out of 17, 4 out of 20, 6
out of 26, and 4 out of 26 laboratories for the four con-
secutive reporting periods.
ISH test-repeat rates for each laboratory are shown in
Table 3. In the first 12 months the overall ISH test-repeat
rate was 8.9 %, decreasing to 8.2 % in the second
12 months for laboratories using CISH. Twelve laborato-
ries changed from using CISH to SISH in the second
12-month period. Repeat rates were higher (13.7 %) in
these laboratories, although this was primarily caused by a
global silver wash contamination issue that was subse-
quently addressed and resolved. In the third 12-month
reporting period, test-repeat rates were 4.9 % for labora-
tories using CISH and 7.2 % for laboratories using SISH.
Table 1 HER2 positivity rates by ISH in early breast cancer tissue samples
























Australian Capital Territory 208 34 (16.3) 310 54 (17.4) 352 67 (19.0) 371 53 (14.3)
New South Wales 3,424 989 (28.9) 5,025 995 (19.8) 6,067 1,021 (16.8) 6,076 870 (14.3)
Queensland 1,423 356 (25.0) 2,205 330 (14.9) 2,811 410 (14.6) 3,151 468 (14.9)
South Australia 827 124 (15.0) 1,060 153 (14.4) 1,254 181 (14.4) 1,247 147 (11.8)
Victoria 1,478 306 (20.7) 2,391 360 (15.1) 2,751 464 (16.9) 3,879 660 (17.0)
Western Australia 475 56 (11.8) 704 86 (12.2) 1,455 181 (12.4) 1,571 176 (11.2)
Tasmania – – 88 11 (12.5) 312 48 (15.4) 292 51 (17.5)
Northern Territorya – – – – – – – –
Total 7,835 1,865 (23.8) 11,783 1,989 (16.8) 15,002 2,372 (15.8) 16,587 2,425 (14.6)
Results from states across Australia recorded over time
HER2 human epidermal growth factor receptor 2, ISH in situ hybridization
a Northern Territory cases were tested at an ISH reference laboratory in New South Wales
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In the final reporting period, test-repeat rates were 3.6 %
for laboratories using CISH and 8.4 % for laboratories
using SISH.
Retesting of discordant IHC/ISH cases
Of the 200 discordant cases selected, four were considered
unsuitable for assessment due to the presence of consid-
erable artifact(s), insufficient tissue, or loss or damage to
the section during processing. Of the remaining 196 cases
retested by IHC, 184 (94 %) showed concordance between
the results of the repeat IHC and ISH. Eleven of the 12
cases that remained discordant (91.6 %) were false-nega-
tive and one was false-positive. The details of these 12
cases are shown in Table 4.
An analysis of the cases that were now concordant fol-
lowing retesting showed that there were 45 cases reclas-
sified from IHC 3? to IHC 2? (equivocal). Of those, 14
(31 %) had a chromosome 17 polysomy. Of the 161 cases
that were originally scored as IHC 3? but did not show
gene amplification by ISH, 116 (72 %) were scored as IHC
0 or IHC 1? after retesting.
Discussion
Since the inception of the Australian In Situ Hybridization
Program in October 2006, the number of HER2 ISH tests
has increased each year; reflecting a shift toward HER2
ISH testing of all breast cancer samples (rather than the
previous practice of triaging samples for ISH testing on the
basis of IHC results). There was a 112 % increase in ISH
testing reported between the first and last time period for
patients with EBC, which is attributable to a greater
understanding of the ISH testing program (i.e., all patients
should be tested for ISH, regardless of IHC results), labo-
ratory implementation of the ISH testing algorithm, and an
increased number of laboratories qualified to report ISH. In
addition, there is greater awareness among oncologists and
breast surgeons that trastuzumab therapy should be avail-
able to all EBC patients with a positive ISH result. By
comparison, ISH reporting of MBC cases was low and
increased by just 20 % between the first and last reporting
periods. Initial ISH testing of MBC cases is not a
requirement of the Herceptin program administered by
Medicare Australia. The smaller increase observed, may
also reflect the fact that many patients presenting with
MBC could have previously had their primary tumor tested
for HER2 and therefore, may have received trastuzumab in
the adjuvant setting [23]. In patients with EBC there was a
reduction in HER2 positivity rates reported between the
time periods (from 23.8 to 14.6 %) which reflects a shift
toward the use of ISH testing for all samples without prior
IHC triaging. The HER2 positivity rate of 14.6 % is
comparable to rates reported in the literature [2–6, 24].
Although the average HER2 positivity rate among patients
with MBC was higher than for EBC for all time periods
and showed variations across the reporting period (22.6,
25.1, 21.3, and 21.6 % for the first, second, third, and
fourth 12-month periods, respectively), these rates were
also similar to those reported in the literature [2–6, 25, 26],
suggesting that MBC is associated with a higher HER2
positivity rate than EBC and reflecting a more aggressive
tumor cohort.



























– – 3 0 (0.0) 12 2 (16.7) 4 0 (0.0)
New South Wales 513 116 (22.6) 336 92 (27.4) 279 63 (22.6) 226 48 (21.2)
Queensland – – 55 12 (21.8) 75 14 (18.7) 85 20 (23.5)
South Australia – – 14 5 (35.7) 61 13 (21.3) 96 14 (14.6)
Victoria – – 54 8 (14.8) 123 27 (22.0) 139 27 (19.4)
Western Australia – – 11 2 (18.2) 34 6 (17.7) 44 21 (47.7)
Tasmania – – – – 8 1 (12.5) 23 3 (13.0)
Northern Territorya – – – – – – – –
Total 513 116 (22.6) 473 119 (25.1) 592 126 (21.3) 617 133 (21.6)
Results from states across Australia recorded over time
HER2 human epidermal growth factor receptor 2, ISH in situ hybridization
a Northern Territory cases were tested at an ISH reference laboratory in New South Wales
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The decision to make trastuzumab therapy available to
patients with HER2-positive EBC following an ISH-posi-
tive test is supported by recent guidelines for HER2 testing
[27], which favor ISH over IHC due to its greater test
accuracy, objectivity, and reproducibility. However, it
should be noted that the use of ISH testing alone is asso-
ciated with some risks, including an increased likelihood of
failing to detect heterogeneity, overscoring highly polyso-
mic cases (when a single probe is used), and missing cases
with low HER2 amplification. IHC is, therefore, a valuable
tool for the assessment of equivocal or difficult cases and
remains an important quality assurance measure. As such,
we feel that the use of ISH testing, together with additional
IHC testing as required, ensures the provision of accurate
testing by all local laboratories, with a central laboratory
providing further evaluation by FISH as necessary.
The efficiency of all laboratories involved in this
nationwide program was illustrated by the consistently
short overall reporting time for ISH tests, with average
reporting times reduced slightly in the second 12-month
period, despite the inclusion of four new laboratories and
the fact that 12 laboratories switched to SISH testing.
Average reporting times remained consistent in the third
and fourth 12-month periods (4.6 and 4.5 days, respec-
tively). For those laboratories that continued to use CISH,
the test-repeat rates also decreased over the reporting per-
iod, reflecting the improvements in testing proficiency as a
result of increasing experience. In the second reporting
period, test-repeat rates were higher than expected for
laboratories using SISH (13.7 %); however, this was
attributed to a contamination of the silver wash which was
reported in a number of countries outside Australia, and the
test-repeat rate fell during the final two reporting periods to
7.2 and 8.4 %, respectively.
This study has demonstrated that there are inherent
inaccuracies in local laboratory staining and/or assessment
of HER2 IHC, where ISH is considered the ‘‘gold stan-
dard’’ test. This is highlighted by the fact that 72% of the
161 cases originally scored as IHC 3? by local laboratories
but found to be non-amplified by ISH were subsequently
scored as IHC 0 or IHC 1? by a central laboratory.
However, our study has shown that very good concordance
(94 %) exists between IHC and ISH when both tests are
performed and interpreted by experienced laboratories and
pathologists. There were a range of factors contributing to
the discordance in the remaining 12 cases, including
monosomy of chromosome 17 (three cases), and clonal
amplification of HER2 (one case). All of these cases
showed only a low level amplification of the HER2 gene
(HER2:CEP17 ratio range 2.3–5.48). There is some debate
regarding the relative importance of HER2:CEP17 ratio
versus HER2 copy number in assessing ISH [28, 29] and
there was discordance between the two methods in 6/12 of
our cases, reflecting the lack of an IHC 3? score.
Although IHC/ISH discordance has been demonstrated
previously in the setting of some clinical trials involving
centralized retesting by FISH [20], our study has focused
specifically on discordant cases. It remains unclear whether
the laboratory test procedure, the pathologist’s interpreta-
tion, or both, contribute to the observed discordances.
Therefore, a valuable additional analysis will be to com-
pare results from small- and large-testing volume labora-
tories; however, this was not possible with the existing
data.
The emphasis on accurate HER2 testing has been
highlighted by the ASCO/CAP expert panel [18]. As well
as recommending an updated scoring system for HER2
assessment, multiple factors that can cause variation in
HER2 testing accuracy were identified, including fixation
Table 3 Average ISH test-repeat rates recorded over time
Laboratory
ID

















1a 6.6 22.2 20.2 13.7
2 – – 1.8 5.2
3 9.0 6.6 6.3 0.0
4a – 13.2 10.8 5.2
5a 6.7 3.7 3.5 8.4
6 2.0 1.6 0.7 0.8
7a – – 0.0 4.5
8a – 10.5 1.4 3.4
9a – 6.5 6.8 6.6
10a 8.4 18.7 22.7 26.8
11a 4.4 3.9 4.9 6.4
12a 16.8 14.7 6.1 13.5
13a 5.9 4.6 8.4 4.9
14a 8.7 8.8 3.1 9.4
15a 10.2 12.4 11.2 0.5
16 – – 1.1 7.7
17 – – 0.0 4.1
18a 5.5 4.2 2.9 7.8
19 23.5 14.3 5.0 2.1
20a 9.0 15.4 5.7 10.7
21 5.3 4.2 4.9 6.1
22a 15.9 13.7 5.9 2.1
23a 6.0 11.2 10.0 5.7
24 5.8 7.3 2.6 2.8
25a 10.6 11.5 4.1 0.4
26a – 37.0 9.5 21.1
ISH in situ hybridization
a Laboratories using silver ISH for the final reporting period
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methods and assay reagents used [18]. Several standard
assays exist for HER2 testing, which could result in a high
degree of testing inaccuracy. The Australian In Situ
Hybridization Program, as well as adhering to the ASCO/
CAP HER2 testing guidelines, uses standardized HER2
testing kits (CISH, SISH, or DuoCISH) to minimize
interlaboratory variation. All pathologists participating in
the Australian In Situ Hybridization Program are required
to perform a minimum number of 50 ISH tests annually,
and each laboratory must perform a minimum of 150 tests
annually. This ensures that there is a sufficient level of
experience in participating laboratories. Participation in
appropriate quality assurance programs is also mandatory.
Further efforts to ensure the implementation of a highly
accurate and robust HER2 testing system as part of this
nationwide program included the emphasis on testing the
excised tumor wherever possible, as testing on core biop-
sies may be less reliable [30]. Our data indicate that core
biopsies were used for HER2 testing in \10 % of cases in
most laboratories.
In summary, these findings demonstrate the successful
implementation of a regulated, nationwide testing program
that continues to collect data on HER2 testing in patients
with breast cancer. We feel that the implementation of a
high standard of training, accreditation, and quality assur-
ance, as well as a streamlined approach to testing and
reporting, have been fundamental to the success of this
program. This methodology could be used as a model for
the establishment of HER2 testing in other countries or for
the implementation of other new biomarker-testing
initiatives.
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